Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec

Bibliographic Details
Main Authors:	Jonathan T. Blackmon, Michael S. Stratton, MD, Young Kwak, MD, Peter G. Pavlidakey, MD, Andrzej T. Slominski, MD, Svetlana B. McKee, RN, BSN, Toni M. Viator, RN, Ju Young Kim, PhD, Conway C. Huang, MD, Robert M. Conry, MD
Format:	Article
Language:	English
Published:	Elsevier 2017-07-01
Series:	JAAD Case Reports
Subjects:	dermal intercalation dermal lymphatics erythematous plaque immune phenotype inflammatory melanoma talimogene laherparepvec
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512617300449

Similar Items

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
by: Dimitrios C. Ziogas, et al.
Published: (2022-06-01)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
by: Howard L. Kaufman, et al.
Published: (2017-09-01)

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
by: Paul V. Ohnesorge, et al.
Published: (2022-06-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
by: Ibrahim Ragab Eissa, et al.
Published: (2017-07-01)

Imaging features of volume replacement using an acellular dermal matrix in oncoplastic breast conserving surgery: A case report
by: Chae Bin Lee, MD, et al.
Published: (2022-06-01)

Nonuremic calciphylaxis manifesting with diffuse dermal angiomatosis
by: Francine T. Castillo, BS, et al.
Published: (2022-06-01)

Nonfollicular papules in the bilateral inframammary region
by: Madiha Khan-Walton, DO, et al.
Published: (2023-10-01)

Sostdc1 Secreted from Cutaneous Lymphatic Vessels Acts as a Paracrine Factor for Hair Follicle Growth
by: Sun-Young Yoon, et al.
Published: (2022-05-01)

Hyperoxia Disrupts Lung Lymphatic Homeostasis in Neonatal Mice
by: Nithyapriya Shankar, et al.
Published: (2023-03-01)

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
by: Yonglu Che, MD, PhD, et al.
Published: (2024-04-01)

Diffuse dermal angiomatosis associated with gestational gigantomastia
by: Kelly Z. Young, BA, et al.
Published: (2023-01-01)

Jarcho-Levin syndrome with diastematomyelia and a dorsal dermal sinus
by: Raja Tamiru, MD, et al.
Published: (2024-02-01)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022-07-01)

Evaluation of dermal corrosion and irritation by Cytoreg in rabbits
by: William Jimenez, et al.
Published: (2021-01-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Tumoral melanosis: A case series of patients with metastatic melanoma after systemic immunotherapy
by: Sophia N. Wix, MPhil, et al.
Published: (2024-03-01)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
by: Kate E. Beekman, BS, et al.
Published: (2023-03-01)

Structural and Functional Changes in Aged Skin Lymphatic Vessels
by: Raghu P. Kataru, et al.
Published: (2022-04-01)

The art of prevention: COVID-19 vaccine preparedness for the dermatologist
by: Shauna M Rice, BS, et al.
Published: (2021-03-01)

Diffuse dermal angiomatosis with clinical features simulating calciphylaxis in the setting of end-stage renal disease
by: Noura Ayoubi, MD, et al.
Published: (2020-09-01)

Annular erythematous plaques in the Marianas
by: Erik A. Kumetz, MD, LT MC USN, et al.
Published: (2020-03-01)

Polyacrylamide hydrogel (Aquamid) filler removal after a decade
by: Young Woong Mo, et al.
Published: (2019-07-01)